Tissium raises €30M in equity funding, €30M in debt

· Source: Tech.eu - Tech.eu · Field: Health & Wellbeing — Medical Devices & Health Technology, Clinical Care & Medical Practice · Depth: Fundamental Awareness, quick

Summary

French MedTech startup Tissium has secured €30 million in Series D-2 equity funding. It also obtained up to €30 million in debt financing from the European Investment Bank, bringing its total equity raised to €200 million. A new US-based family-owned institutional investor led the equity round. Existing investors like Mérieux Développement and Cathay, plus new family offices and high net worth individuals, also supported it. Tissium develops "biomorphic programmable polymers," a novel adhesive technology. This tech reconstructs damaged tissue and restores its natural state, avoiding invasive stitches. It repairs heart defects, hernias, and damaged nerves. Two products, for nerve repair and hernia treatment, have US FDA approval. The new capital will fund US market rollout and clinical trials to expand healthcare applications.

Key takeaway

For investors evaluating MedTech startups, Tissium's €60 million funding round highlights market confidence. This includes €30 million in equity and €30 million in debt for FDA-approved, non-invasive tissue repair technologies. This signals a strong investment opportunity in companies with validated products and clear US market expansion plans. You should prioritize ventures demonstrating both innovative core technology and strategic financial structuring for sustainable growth.

Key insights

Tissium's biomorphic programmable polymers offer a non-invasive tissue repair solution, securing significant funding for US expansion.

Principles

In practice

Topics

Best for: Investor, Entrepreneur, Executive

Related on AIssential

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Tech.eu - Tech.eu.